News BridgeBio two for two as rare disease drug aces ph3 trial BridgeBio's week just went from great to superb, as it reports a second positive topline result in a pivotal trial of a late-stage pipeline drug.
News Merck looking to rare disease deals to build health momentum Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.
News UCB drug for rare disease TK2d boosts survival UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.
News Oculis takes second eye disease therapy into pivotal trials Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data.
News Acadia, Harmony record late-stage rare disease failures Biotechs Acadia Pharma and Harmony Biosciences both suffered setbacks in phase 3 trials of drugs for rare diseases, in one case ending the programme.
News Stealth's patience rewarded as FDA approves Barth drug After a long haul, Stealth BioTherapeutics has finally claimed FDA approval for Forzinity, the first treatment for ultra-rare disease Barth syndrome.
News EMA seeks input on virtual alternative to animal test EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.